Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Al-Ola A Abdallah MD (USMIRC) Profile picture
@Abdallah81MD
Jun 17, 2023 • 7 tweets • 11 min read • Read on X
Scrolly
Flame Cells: These are plasma cells with vermillion-staining glycogen-rich overstuffed fibrils. Although these cytoplasmic features are suggestive of neoplastic plasma cells, can also be found in reactive cells. imagebank.hematology.org/image/3230/fla… #mmsm #myeloma #MedTwitter #USMIRC #MedEd ImageImage
Mott cell is a plasma cell characterized by an accumulation of multiple Russell bodies, globular cytoplasmic inclusions composed of immunoglobulin imagebank.hematology.org/image/61837/mo… #mmsm #myeloma #MedTwitter #MedEd #USMIRC ImageImage
Russell bodies are cytoplasmic inclusions filled with immunoglobulins imagebank.hematology.org/image/4192/rus… #mmsm #myeloma #MedTwitter #MedEd #USMIRC ImageImage
Dutcher bodies (arrow) are intranuclear inclusions found in plasma cells. imagebank.hematology.org/image/1073/dut… #mmsm #myeloma #MedTwitter #MedEd #USMIRC ImageImage
Binucleated plasma cell. atlas.gechem.org/index.php?opti… #mmsm #myeloma #MedTwitter #MedEd #USMIRC ImageImage
inclusion bodies in plasma cells have been repeatedly reported, mainly concentrated in the Auer rod-like inclusions link.springer.com/article/10.100… #mmsm #myeloma #MedTwitter #MedEd #USMIRC ImageImage
Image

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Al-Ola A Abdallah MD (USMIRC)

Al-Ola A Abdallah MD (USMIRC) Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @Abdallah81MD

Al-Ola A Abdallah MD (USMIRC) Profile picture
Jan 18
🧵 Immune Effector Cell–Associated HLH-like Syndrome (IEC-HS) in CAR-T & TCE-treated myeloma and B-cell malignancies
Insights from a large FAERS pharmacovigilance study 👇

1️⃣ IEC-HS is rare but deadly ⚠️
Among >23,000 AE reports, IEC-HS occurred in 1.6%, yet mortality was >60%.
This is not “just CRS”—it’s a distinct, life-threatening hyperinflammatory syndrome 🔥
#mmsm #myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS @US_HMC @Larvol @MedwatchKate @OncoAlertImage
2️⃣ Who reports it most?
Absolute numbers are highest with axi-cel and tisa-cel—but raw counts mislead.
Utilization ≠ risk. We need signal detection, not anecdotes 📊

3️⃣ Disproportionality analysis (2024 data) reveals:
🔺 tisa-cel → ROR 2.2
🔺 cilta-cel → ROR 2.24
⚖️ axi-cel → no disproportionate signal (ROR ~1)
🔽 teclistamab → lower reporting (ROR 0.43)

#mmsm #myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS @US_HMC @Larvol @MedwatchKate @OncoAlert
4️⃣ In Myeloma:
• Cilta-cel had the highest IEC-HS burden among BCMA CAR-T
• TCEs showed fewer cases, but teclistamab IEC-HS carried ~60% mortality 💀
Low frequency ≠ low danger.

#mmsm #myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS @US_HMC @Larvol @MedwatchKate @OncoAlert
Read 7 tweets
Al-Ola A Abdallah MD (USMIRC) Profile picture
Jan 5
🧵Outcomes of pPCL Diagnosed Using the IMWG 2021 Consensus Definition: Retrospective Multicenter #USMIRC Analysis

1️⃣ pPCL in 2025: still ultra–high risk 🧬🔥
New multicenter data using IMWG 2021 criteria (≥5% circulating plasma cells) confirms: prognosis remains poor—but modern transplant strategies matter.
#mmsm #Myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS @US_HMC @MedwatchKate @OncoAlert @LarvolImage
2️⃣ Study snapshot 🧪
📊 67 pts | 2010–2023 | 3 academic centers
• Median age: 64
• High-risk cytogenetics: 60%
• EMD: 24%
• 25% met new pPCL criteria only (5–20% CPC)

#mmsm #Myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS @US_HMC @MedwatchKate @OncoAlert @Larvol
3️⃣ Induction in the real world 💉
Most common regimens:
• PACE-based: 43%
• CyBorD: 27%
• VRd: 15%
ORR after induction: 67%

#mmsm #Myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS @US_HMC @MedwatchKate @OncoAlert @Larvol
Read 11 tweets
Al-Ola A Abdallah MD (USMIRC) Profile picture
Dec 2, 2025
🧵Utility of Neurotoxicity Investigations in CD19 and BCMA CART Recipients with ICANS

1/ Optimizing Neurotoxicity Testing in CAR T-Cell Therapy Recipients

A major retrospective study (n=347) clarifies which neurodiagnostic tests actually help in evaluating ICANS. Spoiler: not all tests are created equal. 👇🧠
#mmsm #MedEd #medtwitter #USMIRC @USMIRCNEWS @OncoAlert @MedwatchKate @US_HMC @Larvol #myeloma #سرطان_الدم #المايلوماImage
2/ Background 🧬
CAR T-cell therapy is transformative for B-ALL, NHL, and MM—but ICANS remains a serious toxicity.
Guidelines conflict on when to use MRI, CSF studies, or EEG, leaving clinicians uncertain. This study bridges that gap. ⚖️

#mmsm #MedEd #medtwitter #USMIRC @USMIRCNEWS @MedwatchKate @US_HMC @Larvol #myeloma #سرطان_الدم #المايلوما
3/ Study Snapshot 📊
• 347 adult CART recipients reviewed
• 41% developed ICANS
• Institutional practice: MRI, LP, EEG at Grade 1 or per clinician discretion
• All patients received prophylactic levetiracetam 💊

#mmsm #MedEd #medtwitter #USMIRC @USMIRCNEWS @MedwatchKate @US_HMC @Larvol #myeloma #سرطان_الدم #المايلوما
Read 12 tweets
Al-Ola A Abdallah MD (USMIRC) Profile picture
Nov 26, 2025
🧵 All #ASH25 abstracts for #mmsm in a tweet 10+ Bonus:

1/10: Presentation ID 2387 
OL-101, a BCMA/GPRC5D dual-targeting autologous CAR-T for relapsed/ refractory multiple myeloma (R/R MM): Results from a Phase I study

#mmsm #Myeloma #USMIRC #MedEd #MedTwitter @USMIRCNEWS @MedwatchKate @Larvol @US_HMC #سرطان_الدم #المايلوما
2/10: Presentation ID 253 
Combined biparatopic nanobody-based B cell maturation antigen chimeric antigen receptor T cell therapy and pomalidomide for relapsed or refractory multiple myeloma: In-vitro characterisation and phase 1 dose-escalation study

#mmsm #Myeloma #USMIRC #MedEd #MedTwitter @USMIRCNEWS @MedwatchKate @Larvol @US_HMC #سرطان_الدم #المايلوما
3/10: presentation ID 2280 
Phase 2 study of aponermin +kt-decp in patients(pts) with Relapsed/Refractory multiple myeloma and extramedullary disease

#mmsm #Myeloma #USMIRC #MedEd #MedTwitter @USMIRCNEWS @MedwatchKate @Larvol @US_HMC #سرطان_الدم #المايلوما
Read 11 tweets
Al-Ola A Abdallah MD (USMIRC) Profile picture
Nov 21, 2025
7/10 Abstract from #ASH25:

1/🚀 Phase 2 IMMUNOPLANT Study Update!
Exploring abbreviated, fixed-duration (4 cycles) linvoseltamab (Linvo) immuno-consolidation to deepen responses in newly diagnosed multiple myeloma patients who remain MRD-positive after triplet/quad therapy.
A study from USA 🇺🇸
#Myeloma #Oncology

#mmsm #myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS @OncoAlert @MedwatchKate @Larvol @US_HMC #المايلوما #سرطان_الدم
2/🧬 Why this matters:
Even with modern quadruplet regimens (PI + IMiD + anti-CD38), about 50% of NDMM patients stay MRD-positive.
Linvoseltamab (a CD3xBCMA bispecific) may push responses deeper — without HDM-ASCT for those who defer it.
#mmsm #myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS @OncoAlert @MedwatchKate @Larvol @US_HMC #المايلوما #سرطان_الدم
3/📝 Study design:
✔️ Single-center Phase 2
✔️ Up to 25 evaluable NDMM pts
✔️ Must have VGPR+ but MRD-positive by clonoSEQ
✔️ Receive 4–6 cycles of Linvo (step-up dosing)
✔️ Primary goal: MRD conversion
Secondary goals: sustained MRD-negativity, PFS, OS, safety

#mmsm #myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS @OncoAlert @MedwatchKate @Larvol @US_HMC #المايلوما #سرطان_الدم
Read 10 tweets
Al-Ola A Abdallah MD (USMIRC) Profile picture
Nov 16, 2025
5/10 ASH abstracts in #myeloma #ASH25
This one must make the list!!

🧵1/🚀 Promising new real-world data from China 🇨🇳!

Equecabtagene autoleucel (eque-cel) after ASCT shows strong safety & efficacy in ultra–high-risk multiple myeloma (UHR-MM) patients.
#MedEd #MedTwitter #mmsm #myeloma #USMIRC @USMIRCNEWS @MedwatchKate @Larvol @US_HMC @OncoAlert @oncodaily #سرطان_الدم #المايلوما
2/🧬 Why it matters:
UHR-MM patients still face poor outcomes despite advances in MM therapy. New strategies are urgently needed. Eque-cel, a BCMA-CAR-T therapy, is being explored earlier in treatment.

#MedEd #MedTwitter #mmsm #myeloma #USMIRC @USMIRCNEWS @MedwatchKate @Larvol @US_HMC @OncoAlert @oncodaily #سرطان_الدم #المايلوما
3/🧪 Study design:
Retrospective review of 12 UHR-MM patients treated with ASCT ➜ eque-cel (Day 2–4).
UHR defined by:
• High-risk cytogenetics (del17p ≥60%, TP53, t(4;14), etc.)
• Primary refractory disease
• Early relapse
• Primary PCL history

#MedEd #MedTwitter #mmsm #myeloma #USMIRC @USMIRCNEWS @MedwatchKate @Larvol @US_HMC @OncoAlert @oncodaily #سرطان_الدم #المايلوما
Read 10 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

Send Email!

:(